Novartis Willing To “Walk Away” From Chiron Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
Chiron’s business is “strategically attractive,” but the company faces several challenges, particularly in vaccine manufacturing, Novartis CEO Vasella says.
You may also be interested in...
Chiron Seeking To Bump Up Buyout Bid? Directors Reject Novartis’ Offer
A $4.5 bil. cash offer from Novartis for an outstanding 57.8% stake in Chiron is “inadequate,” according to Chiron’s independent directors.
Chiron Deal Offers Novartis Entry Into Vaccine Business
Novartis seeks to acquire remaining 57.8% of Chiron it does not already own with an all-cash bid of $4.5 bil.
Chiron Anticipates Fluvirin Shipments Will Begin In Late September/Early October
Company has several remaining regulatory hurdles before flu vaccine reaches the market.